Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27424148.
- Also identified by DOI 10.1016/j.jcyt.2016.06.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Type 1 diabetes mellitus (T1DM) is an autoimmune disease causing progressive destruction of pancreatic β cells, ultimately resulting in loss of insulin secretion producing hyperglycemia usually affecting children. Replacement of damaged β cells by cell therapy can treat it. Currently available strategies are insulin replacement and islet/pancreas transplantation. Unfortunately these offer rescue for variable duration due to development of autoantibodies. For pancreas/islet transplantation a deceased donor is required and various shortfalls of treatment include quantum, cumbersome technique, immune rejection and limited availability of donors. Stem cell therapy with assistance of cellular reprogramming and β-cell regeneration can open up new therapeutic modalities. The present review describes the history and current knowledge of T1DM, evolution of cell therapies and different cellular therapies to cure this condition.
Medical subject headings
- Cell- and Tissue-Based Therapy
- Diabetes Mellitus, Type 1
- Insulin
- Stem Cell Transplantation
- Stem Cells